Thanks, Stefan.
me ECO of business announcements Slide mentioned.Starting an Synthesis the business overview some provide on our Manufacturing of recap and Pharmaceutical X. the we let recent development with commercial our manufacturing Stephen platform, Before progress
game-changing During manufacturing we manufacturing pharmaceutical for was Synthesis platform. plan our year, ECO and foundational to on to our that biocatalysis revenue-generating restructuring develop you our potentially told the business last focus
and to then, an in also with of We reach. right leveraging view as committed series as monetizing our announcements, that assets. confirmation Stephen I we by on we consistent commercial exciting have execution our are focusing deals portfolio and Since efforts partners noted, the our products broader completed
strong and the can this enzyme value manufacturing in they terms scientific double-stranded and up and Our the path mRNA meaningful of product market wild-type a Codex perspective on today.For contamination, rapid HiCap its from variant commercial the arena. their compelling this a offered represents GMP manufacturing From and version this step RNA to reduced polymerase capping existing efficiency both a improved enzyme. given example. Aldevron Aldevron, our footprint RNA is maximize from a standpoint, Offering a great is available
we burn while CDX-XXXX for Science's us our potential this providing in landscape, commercial hands payments look global of Putting discontinuation to for combined Given the cultivate. Aldevron's DNA reduce family relationship and is we building mRNA development milestone exclusive forward Nestle mid-single-digit manufacturing also July. in payment Danaher a followed leadership an of we'll Health going valuable to X, biotherapeutics cash purchase ligase, last investment upfront to significantly RNA which additional Nestle our the and manufacturing the partnership in seen the broader Slide upfront eventual our long-term million the announced evolving in of companies.As announced with technical Roche reaching a newly of on of We Aldevron an milestones and allowed with double-stranded out-license engineered receive and royalties.Finally, where million $X payments. forward, agreement CDX-XXXX, upon
ECO our and business.Before a to returns manufacturing our I'd costs to find milestones, high-value who Importantly, partners deal monetize enzyme. Synthesis foundational share the enzyme project, like to upcoming are commercial more healthy take shift extend particular to develop Shifting multiple a our customer's a are this we process. that ability to demonstrate it first about on Slide to When a evolution and our fit or that have covering what These pharmaceutical I to over assets it off-the-shelf our requires needs is to optimize can reach customer to a step to platform manufacturing API this noncore their approaches the for will engineered business. whether potential about enzyme manufacturing moment determine an us X. enzyme whether examples
clinical we completed manufactured enzyme, this clinical usually in be to a Over XX gram-level used even be to development identify quantities selected than quantities variants work requirements, can in the generate years, and thousands enzyme requires ability support kilogram Once the variants sometimes weeks. the few less business us which the enzyme X in existing fee-for-service plans.When the generated for process classes, gives of the use months support and full of some have a across trials. last commonly meets evolution customer customers' that quickly to can we in formulation enzyme customer
we to the clinic, As can quickly enzyme the scale the product enters kilogram quantities.
is the evolution future their selection take goal support to as evolution kilogram process revenues.The enzyme years fee-for-service enzyme to clinical and potential enzyme While our trials launch. and ultimate are product revenue, can provide quantity customized to several a R&D finally, from commercial These recognized is eventual as product our variant be product products the our where variant used the chemical customer's driving clinical we funnel enzyme with clinical long-term new to enzyme must fill for trial reduce programs basis. product continue to steps screening through of Therefore, enzymes moves can and replace stage overall revenue growth, classes one and costs. production
existing to development areas, years, the experiences for we and customer where that enzymatic management an In drive Over an comes dedicated drug account growth approved. to business all already we to commercially us order develop have in these is also personnel. route had key a have
late-stage growth product we segment.On sustain the throughout screening already we've in seen increase just programs revenue I As decade. have on transitioned these pharmaceutical we custom refer upon in this a are to see new the to development and for understand as XX for enzymes II these III customers enzyme or X with needs already product target moving products. as indication, That when next on the Phase currently new based pipeline said, mentioned, mid-sized the we to result, and launch.As reaches the slide, production meaning of trials. we selling scale has enzymes and the growth early pharma This we much a an clinical Typically, indication Codexis. new to can the drug programs, the candidate drug the further Once candidate engineered manufacturers of candidate's that annual are revenue potential commercial clinical you remain disclosed named X, to to usually R&D of trials. occurs forecast years Slide is building customer name out better future Phase support focused our for clinical drug kilogram can expected
are all to sustain successful, -- as programs growth. these number product clinical While pipeline not to is revenue maintain number programs of a future year-to-year fluctuates from of named while this consistent our goal programs
avoid product to to product at why we factors unpredictable. each year, tends all annual typically provide of revenue manufacturing be mind When we continue that these product to the look or customers, of in this leaders, and have seasonality business as our or customer revenues needs across quarter-over-quarter of efforts demand in sustainable, quarterly no named expect primarily the is XX% product nonbinding of are you of we of make we they historical flows Keep why shortages. consistent to and contribute as at start revenue visibility stockpile While will of guidance into when to clear revenues, account changes is When through this forecast to well somewhere trend visibility changes product their procurement key and they between to our enzyme understanding when a and ebbs to growth drug be forecast our binding XX% combination management. business. see which programs.Maintaining there development need
large on in X the Big customers, development, X. the programs named revenues If active demand our down to our Synthesis model.As our across we indications, the platform manufacturing Big of commercial reminder, our engineered Big result, Slide revenues of XX large i.e., More custom to from ECO for clinical customer pharma enzymes, future.Turning and and disorders. pipeline the communication enzymes majority X to sense be continues XX% than X the X sell overall product selling a expect a to which of driving future neurological successful currently to X cancer, drugs we including the or are As comes of XX. in become market come diabetes we product
track meeting an that anticipate Synthesis that the full-length TIDES remain this first Stefan Innovation begin conversations enzymatically rapidly and and from the customers. the pharma to presentation platform conversations access will to May. these forward for us year. commercial looking early translate large progress customers siRNA Between and U.S. we in expected build-out we his our demonstrations XXXX.Technical Lab, license access and the our to with at synthesized demonstration will our November on early already As a concrete ECO at with an into about interactions half of Stefan the several potential of customers customers CDMO allowed second of team mentioned, EU theoretical has one large shift Ideally, in of presented important we in of TIDES capabilities, in are the to
with Recall future ligase, them customers ecoRNA from we half molecules of production provide this with customers will us solution the win a can to large to ligase space. which provide year. impurities offering supports customers siRNA chemistry-built multiple we to complete Synthesis to of to CDMO ligase platform anticipate which have that double-stranded GLP-grade addition, the ability to several from different And the enhances customers ability the with Innovation our programs Lab solution phosphoramidite of large market of double-stranded with this near-term and lengths. in GMP-grade customized along shorter make customers, a the Innovation ECO pharma a development from enable already build players major pharma In in provides excited potential manufacturing for for for Having provide the siRNA.Finally, product RNA the potential license blueprint anticipate sufficient second segments. preclinical ability double-stranded the ECO Synthesis future allows fragments be and manufacturing to we that that our together. plan we thrilled I'm really to joined solution to platform the ECO available because This Synthesis directly directly innovators, candidates. increasing full-length our the I'm ability reduces ongoing The share costs siRNA smaller Lab us to RNA their
to important our results with the win from manufacturing.With we is turn to many financial we to made engage the and ways I'll takeaway approaches have progress to that, Sri have our discuss The call today enzymatic that guidance. customers and over with XXXX RNAi
